Evidence map›Paper›PMID 39757718›Full record

ArticleFEBS open bio2025

CD44v, S1PR1, HER3, MET and cancer-associated amino acid transporters are promising targets for the pancreatic cancers characterized using mAb.

Takashi Nakano, Kouki Okita, Shogo Okazaki, Soshi Yoshimoto, Sachiko Masuko, Hideki Yagi, Kazunori Kato, Yoshihisa Tomioka, Kenichi Imai, Yoichi Hamada and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS open bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Takashi NakanoCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Kouki OkitaCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Shogo OkazakiCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.ORCID https://orcid.org/0009-0008-2243-5140
Soshi YoshimotoCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Sachiko MasukoCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Hideki YagiCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Kazunori KatoFaculty of Health and Sports Sciences, Toyo University, Kita-ku, Japan.
Yoshihisa TomiokaOncology Pharmacy Practice and Science, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai-shi, Japan.
Kenichi ImaiDepartment of Microbiology, Division of Immunology and Pathobiology, School of Dentistry, Nihon University, Chiyoda-ku, Japan.ORCID https://orcid.org/0000-0003-0985-4267
Yoichi HamadaHamada Clinic, Higashiosaka-shi, Japan.
Kazue MasukoCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Kayoko Shimada-TakauraNatural Drug Resources, Faculty of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Noriaki NagaiAdvanced Design for Pharmaceuticals, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.
Hideyuki SayaOncology Innovation Center, Fujita Health University, Toyoake-shi, Japan.
Tomio AraiDivision of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Japan.
Toshiyuki IshiwataDivision of Aging and Carcinogenesis, Research Team for Geriatric Pathology, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Itabashi-ku, Japan.
Takashi MasukoCell Biology Laboratory, School of Pharmacy, Kindai University, Higashiosaka-shi, Japan.ORCID https://orcid.org/0000-0002-2410-2007

Funding

MEXT/JSPS KAKENHI 18H05463
6 · The paper itself

Abstract

Effective therapies have yet to be established for pancreatic ductal adenocarcinomas (PDAC) even though it is the most aggressive cancer. In the present study, PDAC was analyzed using novel rat mAbs against membrane proteins in conjunction with flow cytometry and immunohistochemistry. Human epidermal growth receptor (HER)1-4, mesenchymal to epithelial transition factor (MET), sphingosine-1-phospahate receptor 1 (S1PR1), l-type amino acid transporter 1 (LAT1), system x

Indexed as

Amino Acid Transport SystemsAntibodies, MonoclonalCarcinoma, Pancreatic DuctalHyaluronan ReceptorsPancreatic NeoplasmsAnimalsCell Line, TumorHumansMiceProto-Oncogene Proteins c-metRatsReceptor, ErbB-3Sphingosine-1-Phosphate ReceptorsXenograft Model Antitumor AssaysAmino Acid Transport SystemsAntibodies, MonoclonalCD44 protein, humanERBB3 protein, humanHyaluronan ReceptorsProto-Oncogene Proteins c-metReceptor, ErbB-3S1PR1 protein, humanSphingosine-1-Phosphate Receptorsamino acid transporterCD44vHER3METpancreatic cancerS1PR1

Identifiers

PMID39757718
PMCPMC12051033

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.